Linked Life Data

19468200

Source:http://linkedlifedata.com/resource/pubmed/id/19468200

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2009-8-12
pubmed:abstractText
Cutaneous sarcoidosis may be a chronic disease with important morbidity requiring aggressive therapy. The efficacy of different anti-tumor necrosis factor alpha(anti-TNF-alpha) treatments in refractory cutaneous and systemic sarcoidosis has been reported previously. We report the first patient with chronic cutaneous sarcoidosis who responded to dose escalation of anti-TNF-alpha agents that have been ineffective at the standard dosage, illustrating that the optimal dosing regimen has still to be defined for this indication before considering difficult-to-treat patients as nonresponders. Our case report also illustrates that the fusion protein etanercept, even used at a high dosage, may be less effective for the treatment of cutaneous sarcoidosis than the monoclonal antibodies infliximab and adalimumab.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1421-9832
pubmed:author
pubmed:copyrightInfo
2009 S. Karger AG, Basel.
pubmed:issnType
Electronic
pubmed:volume
219
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
59-62
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists.
pubmed:affiliation
Dermatology Department, Hôpitaux Universitaires de Genève, Geneva, Switzerland. anne-marie.thielen@hcuge.ch
pubmed:publicationType
Journal Article, Case Reports